HBM BioVentures

de

Monthly Overview

Quarterly Overview

Largest Investments

Private Companies

Specialised Venture Capital Funds

Public Companies

Specialised Venture Capital Funds as at 30.6.2010

A. M. Pappas Life Science Ventures II
BioMedInvest I
BioMedInvest II
BioVeda China
BioVentures Investors II
EMBL Technology Fund
Galen Partners V
Hatteras Venture Partners III
Heidelberg Innovation BioScience Ventures II
MedFocus Fund II
Nordic Biotech
Skyline Venture Partners III
Symphony Capital Partners
Water Street Healthcare Partners

For details in investments in specialised venture capital funds, please click here:

News

Press Releases
»	HBM BioVentures Quarterly Report as at 30 June 2010
»	HBM BioVentures’ largest public investment – Micrus – acquired by Johnson & Johnson
»	HBM BioVentures sells USD hedging position at a profit
»	Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM BioVentures shares and intensify cooperation
»	Archive

Financial Reports

»	Quarterly Report June 2010
»	Annual Report 2009/2010
»	Archive

Share Price

SIX Swiss Exchange Ticker
HBMN

Key Figures

as at 31.8.2010	CHF

NAV per share	62.58
Net assets	616 Mio.

Search

News Registration